Imbria Enrolls First Patient in the Phase 2 IMPROVE-DiCE Clinical Trial Evaluating Ninerafaxstat in Patients with Heart Failure with Preserved Ejection Fraction
09 janv. 2023 08h00 HE
|
Imbria Pharmaceuticals Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today announced...
Imbria Presents Positive Clinical Data for Ninerafaxstat from IMPROVE-DiCE at the European Society of Cardiology Congress 2022
26 août 2022 08h15 HE
|
Imbria Pharmaceuticals Inc.
BOSTON, Mass., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company developing novel therapies designed to enhance cellular energetics, today...
Imbria Pharmaceuticals to Present Phase 2a Data from the Ninerafaxstat Program at the European Society of Cardiology Congress 2022
22 août 2022 08h00 HE
|
Imbria Pharmaceuticals Inc.
BOSTON, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Imbria Pharmaceuticals, Inc., a clinical stage, cardio-metabolic company developing novel therapies designed to enhance cellular energetics, today...